ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

9:00AM-11:00AM: Abstract Number: 0280

Compliance and Validation of Patient Reported Outcome Information Collected from Lupus Patients Using a Mobile Application

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

9:00AM-11:00AM: Abstract Number: 0100

Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Abstract Number: 0293

Contraction of the Stool Taxa Clostridia Is Associated with the Development of Clinical Disease Among Anti-Ro+ Mothers of Children with Neonatal Lupus

SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0413

Coronavirus Infection and Vasculitis: Identifying Associations Mining the Biomedical Literature

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0252

Corticosteroid and Opioid Use Remain High in Systemic Lupus Erythematosus Patients Receiving Biologic Therapy: A Retrospective Claims Database Analysis

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

9:00AM-11:00AM: Abstract Number: 0163

Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach

Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Abstract Number: 0153

Counseling on Safe Driving Strategies in Patients with Osteoarthritis and Rheumatoid Arthritis

Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Abstract Number: 0015

COVID -19 Lung Inflammation – What Have We Learnt so Far ?

Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0008

COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review

Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0051

COVID-Related Distress and Mental Health in Adult Rheumatology Patients During the COVID-19 Pandemic

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 0285

CXCL13 Neutralization Reduces Neuropsychiatric Manifestations in MRL/lpr Mice

SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0027

CYP2D6 Genotype and Reduced Codeine Analgesic Effect in Real-World Clinical Practice

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 0312

Dactylitis Is Associated with Greater Disease Severity, Ultrasound Synovitis, and Erosive Damage, in Very Early DMARD Naïve Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0423

Defining Ear Chondritis: Data from 685 Patients with Relapsing Polychondritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0391

Defining the Optimal Disease Duration of Early Diffuse Systemic Sclerosis for Clinical Trial Design

Systemic Sclerosis & Related Disorders – Clinical Poster I

«Previous Page
1
…
5
6
7
8
9
…
35
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].